Synergen lineage may finally pay off

Alper, Joseph
March 1999
Nature Biotechnology;Mar1999, Vol. 17 Issue 3, p217
Academic Journal
Reports on the business performance of Boulder, Colorado-based Array BioPharma Inc. as of March 1999. Corporate background of Array; Business strategies adopted by Array to generate income in the short term; Analysts' assessment of Array's business strategies.


Related Articles

  • ARRAY BIOPHARMA REPORTS 3RD QTR NET LOSS OF 14 MILLION.  // Biotech Financial Reports;Jun2007, Vol. 14 Issue 6, p3 

    The article reports that Array Biopharma Inc., a biopharmaceutical company, has revealed net loss of $14 million in financial assets for the third quarter of fiscal 2007 in Boulder, Colorado. Array's revenue has decreased from $11.7 million in 2006 to $10.4 million in 2007. The revenue results...

  • CLINIC ROUNDUP.  // BioWorld Today;6/21/2007, Vol. 18 Issue 120, p6 

    This section offers news briefs related to the pharmaceutical industry. Alexza Pharmaceuticals Inc. has begun a Phase IIa proof-of-concept trial with AZ-104 in patients with migraine headache. Altus Pharmaceuticals Inc. presented an investigational new drug application for ALTU- 237, a...

  • CLINIC ROUND UP.  // BioWorld Today;8/6/2007, Vol. 18 Issue 151, p5 

    The article reports on clinical trials initiated by several pharmaceutical companies. Array BioPharma Inc. filed an investigational new drug application with the FDA for ARRY-380. Hana Biosciences has initiated a multicenter Phase II clinical trial of Marqibo in adult patients. ImmunoCellular...

  • ALLIANCE/COLLABORATIONS.  // Drug Discovery & Development;Feb2002, Vol. 5 Issue 2, p28 

    Reports several strategic alliances and collaborations in the pharmaceutical industry. Agreement between Neurotech S.A. and Amgen Inc.; Initiation of a drug discovery Amgen Inc. and Array BioPharma Inc.; Collaboration between PIERES Proteolab AG and CytoTools GmbH.

  • Takeda and Array BioPharma Enter Drug Discovery Pact.  // Chemical Market Reporter;4/12/2004, Vol. 265 Issue 15, p2 

    Reports on Takeda Chemical Industries Ltd.'s signing of a second drug discovery deal with Boulder, Colorado-based Array BioPharma Inc. to develop small-molecule drug candidates against a Takeda target.

  • Active Pharmaceuticals Ingredient Watch.  // Chemical Market Reporter;1/21/2002, Vol. 261 Issue 3, p14 

    Presents an update on the pharmaceutical industry as of January 21, 2002. Sales growth posted by Abbott Laboratories Inc. in 2001; Series of nonexclusive agreements signed by Array Biopharma Inc.; Joint venture company established by Bachem Ltd. and Berna Biotech.

  • CLINIC ROUNDUP.  // BioWorld Today;11/21/2007, Vol. 18 Issue 227, p2 

    This section offers news briefs in the pharmaceutical industry. Dosing of its small-molecule p38 inhibitor ARRY-797 has been commenced by Array Biopharma Inc. in a Phase II trial to evaluate its efficacy for pain in dental patients undergoing third molar extraction. Data has been reported by...

  • Celgene Pays Array $40M In Drug Discovery Deal.  // Bioworld Week;10/1/2007, Vol. 15 Issue 40, p3 

    The article discusses the payments received by Array BioPharma Inc. in Boulder, Colorado which values at $40 million from Celgene Corp. for a drug discovery deal for cancer and inflammatory disease. According to Array's chief executive officer Robert Conway, the Celgene deal is considered as one...

  • Clinic Roundup.  // BioWorld Today;7/3/2013, Vol. 24 Issue 127, p7 

    This section offers news briefs related to the pharmaceutical industry in the U.S. as of July 2013. Array BioPharma Inc. achieved success in conducting a trial in patients with low-grade serous ovarian cancer (LGSOC). The results of a study on the Alprolix long-lasting clotting factor was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics